E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis

Hiba Salam, Bhagyalekshmi Narayanapillai, Ramesh Mohan.

Abstract
Background: Ulcerative Colitis (UC) is an inflammatory disease affecting the colonic mucosa. Oral Mesalazine is one of the established treatments for UC and the conventional dosing regimen is 3 times a day. However, medical management favors lesser dosing frequency and the evidence of once daily dosing efficacy is not established by randomized controlled trials.

Aim and Objective: Aim and objective of the study was to assess the efficacy and safety of once daily versus 3 times daily Mesalazine in UC.

Materials and Methods: This prospective study was carried out in a sample of patients newly diagnosed with mild to moderately active UC. Patients were grouped into to once daily and 3 times daily groups. Outcomes were measured by Partial Mayo score, Individual Symptom Assessment, endoscopy and Histological score at the end of 8th week. Primary endpoint was proportion of patients achieving clinical remission and response with Partial Mayo score at the end of 8th week from start of treatment. Analysis was done using Epi Info Version 7.

Results: Sixty patients were assessed (31 patients in OD group and 29 patients in TID group). 61.3% patients in OD group and 62.1% in TID group achieved remission, whereas 71% in the OD group and 58.6% in the TID group achieved clinical response to treatment at the end of 8th week with Partial Mayo score.

Conclusion: The study concludes that once daily dosing regimen of Mesalazine is as efficacious and safe as 3 times daily dosing regimen in inducing remission in mild to moderate UC.

Key words: Oral Mesalazine; Ulcerative Colitis; Once Daily Dose; Three Times Daily Dose


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Hiba Salam
Articles by Bhagyalekshmi Narayanapillai
Articles by Ramesh Mohan
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Salam H, Narayanapillai B, Mohan R. A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis. Natl J Physiol Pharm Pharmacol. 2021; 11(12): 1394-1398. doi:10.5455/njppp.2021.11.10363202116102021


Web Style

Salam H, Narayanapillai B, Mohan R. A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis. http://www.njppp.com/?mno=130349 [Access: January 01, 2022]. doi:10.5455/njppp.2021.11.10363202116102021


AMA (American Medical Association) Style

Salam H, Narayanapillai B, Mohan R. A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis. Natl J Physiol Pharm Pharmacol. 2021; 11(12): 1394-1398. doi:10.5455/njppp.2021.11.10363202116102021



Vancouver/ICMJE Style

Salam H, Narayanapillai B, Mohan R. A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis. Natl J Physiol Pharm Pharmacol. (2021), [cited January 01, 2022]; 11(12): 1394-1398. doi:10.5455/njppp.2021.11.10363202116102021



Harvard Style

Salam, H., Narayanapillai, . B. & Mohan, . R. (2021) A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis. Natl J Physiol Pharm Pharmacol, 11 (12), 1394-1398. doi:10.5455/njppp.2021.11.10363202116102021



Turabian Style

Salam, Hiba, Bhagyalekshmi Narayanapillai, and Ramesh Mohan. 2021. A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis. National Journal of Physiology, Pharmacy and Pharmacology, 11 (12), 1394-1398. doi:10.5455/njppp.2021.11.10363202116102021



Chicago Style

Salam, Hiba, Bhagyalekshmi Narayanapillai, and Ramesh Mohan. "A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis." National Journal of Physiology, Pharmacy and Pharmacology 11 (2021), 1394-1398. doi:10.5455/njppp.2021.11.10363202116102021



MLA (The Modern Language Association) Style

Salam, Hiba, Bhagyalekshmi Narayanapillai, and Ramesh Mohan. "A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis." National Journal of Physiology, Pharmacy and Pharmacology 11.12 (2021), 1394-1398. Print. doi:10.5455/njppp.2021.11.10363202116102021



APA (American Psychological Association) Style

Salam, H., Narayanapillai, . B. & Mohan, . R. (2021) A comparative study evaluating the efficacy and safety of once daily versus three times daily mesalazine in ulcerative colitis. National Journal of Physiology, Pharmacy and Pharmacology, 11 (12), 1394-1398. doi:10.5455/njppp.2021.11.10363202116102021